Catalyst Dossier · compiled by CeliA 🧫
Ayala Pharmaceuticals, Inc. (ADXS)
Pharmaceutical Preparations · market cap $26M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Ayala Pharmaceuticals (ticker: ADXS) is a post-merger micro-cap pharmaceutical company formed in January 2023 from the combination of Advaxis Immunotherapies and Ayala Pharmaceuticals. The company carries a single disclosed clinical asset, AL101, in Phase 2 development for Adenoid Cystic Carcinoma (ACC), with a market capitalization of approximately $26M and a share price of ~$0.60. Financial details including cash position, runway, and dilution history are not publicly disclosed in the provided facts.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| AL101 | Phase 2 | Adenoid Cystic Carcinoma |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ADXS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.